



## Press Release |

### **IBA has opened its first PET radiopharmaceutical center in India and will further increase its capacity**

Embargo until 5:40 pm (Belgian time) – August 28, 2006

**Louvain-la-Neuve, Belgium, August 28 2006** – IBA (Ion Beam Application S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) has announced today that its division, IBA Molecular, has started the production and distribution of FDG, the most needed radiopharmaceutical used in PET (Positron Emission Tomography) imaging, in Noida, on the suburb of Delhi, India. IBA Molecular plans to open a new production center in Mumbai, India in the near future.

The IBA radiopharmaceutical production center in Noida, inaugurated in March 2006 by the Walloon Minister for Economy and Foreign Trade, Jean-Claude Marcourt, was set up in record time with its Joint Venture Indian partner, and is now the first and only private facility in India offering a daily distribution of FDG. For the second facility in Mumbai, which is foreseen to be operational in the near future, land has been already identified and building construction is expected to start soon.

PET is a unique, state-of-the-art technique used to diagnose cancer at a very early stage, with unmatched precision, and to follow the effects of treatment. It is also used to monitor patients with neurological disorders and heart disease. A standard PET imaging procedure is most commonly done by injecting the patient with a dose of radiolabeled FDG (fluorodeoxyglucose) and then using a PET scanner to produce a 3D digital image from the energy emitted by the FDG. The interpreter will assess the distribution of the FDG in the patient's body, and identify areas of an increased concentration of FDG, which may represent potential disease.

“The availability of FDG is a major advancement for the healthcare community in New Delhi, India. The safe and reliable supply of FDG will facilitate the private diagnostic imaging centers' ability to offer PET scanning to oncology patients”, commented Dr. Ajay Aggarwal of the Diwan Chand Satyapal Aggarwal Imaging Research Center. “The PET scan can be used to detect the level of chemical and metabolic changes in diseased organs with the goal of improving the diagnosis and staging of cancer. We appreciate IBA for taking this step forward by installing the first FDG production center in India at New Delhi”, Dr. Aggarwal continued.



## Press Release |

IBA, the sole FDG supplier present on three continents, owns fully or partially 15 radiopharmaceutical facilities in North America, 19 in Europe and is now offering FDG in Asia. Through this global distribution network, IBA can supply radiopharmaceuticals to be used for PET scanning daily to some of the most densely populated areas around the world.

“Our network's global expansion confirms our intention of strengthening our leading position in the field of PET radiopharmaceutical production and distribution to diagnose cancer and other serious diseases, a crucial segment for IBA”, commented Pierre Mottet, Chief Executive Officer. “Specifically, the expansion in India will strengthen FDG product availability and guarantees quality and speed to all our new and potential clients throughout this country”.

### **About IBA**

IBA delivers solutions of a unique precision in the fields of **cancer diagnosis and therapy**. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to BelMid index.

Website: <http://www.iba-worldwide.com>

### Contact

#### **IBA**

Paul-Emmanuel Goethals  
Director, Corporate Business Development  
& Investor Relations  
Tel.: +32 10 47 58 16  
[paul-emmanuel.goethals@iba-group.com](mailto:paul-emmanuel.goethals@iba-group.com)

#### Local contact for India

Rakesh Pathak - Manoj Nair  
Diago D off Carter Road  
Bandra West, Mumbai, India  
Tel.: +91 22 264 83 333  
+91 98 214 33 052